Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 3-month safety study of tradipitant in idiopathic or diabetic gastroparesis
2023-503802-35-00Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of tradipitant in idiopathic gastroparesis (IG) and gastroparesis, sponsored by Vanda Pharmaceuticals Inc. Started Dec 2024; status: completed.
02
Drugs
tradipitant
03
Conditions
idiopathic gastroparesis (IG)gastroparesis
Beyond the preview
Go deeper on 2023-503802-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503802-35-00.